Heredity

GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer

Retrieved on: 
Mittwoch, Mai 29, 2024
ASX, Genomics, Sporadic disease, GTG, Ovarian cancer, Genetic testing, Risk, Krystal Barter, Diagnosis, Health, Breast cancer, Cancer, Death, Woman, Breast, Heredity, Risk assessment, Birth control

The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease.

Key Points: 
  • The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease.
  • Launched at the inaugural “Know Your Risk” event in California, USA, the event provided invaluable insights of the role of genomics in women’s health.
  • This new geneType Comprehensive Risk Assessment test represents a significant leap in preventative healthcare, whereby clinicians will have a complete understanding of their patient’s risk profile of developing one of the deadly cancers.
  • Ovarian cancer is more deadly and is among the leading cause of cancer deaths in women¹.

QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support

Retrieved on: 
Dienstag, Mai 14, 2024
NGS, IVDR, Quality management system, Human, Organization, Genetic testing, Class, QGEN, Artificial intelligence, Sale, Medical device, Certification, Senior, Somatic, Machine learning, Classification, QIAGEN, Heredity, Acceleration, European

QIAGEN Clinical Insight Interpret is the first NGS interpretation platform to be certified under IVDR for both oncology and hereditary applications.

Key Points: 
  • QIAGEN Clinical Insight Interpret is the first NGS interpretation platform to be certified under IVDR for both oncology and hereditary applications.
  • As a medical device software for clinical decision support (Class C IVD Medical Device) it conforms with regulatory policy, ensuring greater patient protection, information transparency, and data traceability.
  • “Receiving IVDR certification for QIAGEN Clinical Insight Interpret is further confirmation that our clinical customers benefit from a high-quality and regulatory compliant software that allows scaling and acceleration of critical turn-around times and workflow efficiencies,” said Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights.
  • QIAGEN Redwood City, the development site of the QIAGEN Clinical Insight Interpret platform, has ISO 13485:2016 certification for its Medical Devices and Quality Management Systems based on the QIAGEN Clinical Insight Interpret product.

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, April 10, 2024
Abele, AAAAI, FDA, Citizenship, Research, Healthcare Improvement Scotland, Trial of the century, SMC, IND, Record, Intellectual property, National Congress, American Academy, Attack, Food, ACAAI, Conference, Hereditary angioedema, MHRA, HAE, Therapy, Network, EOP, Book, PRO, Chemistry, CMC, G&A, Investigational New Drug, Doctor of Philosophy, Medication, Research and development, American College, Mass meeting, Health care, Administration, Bank statement, Annual general meeting, Heredity, Pharmaceutical industry

Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.

Key Points: 
  • Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.
  • Effective April 15, 2024, David Nassif, J.D., will join Pharvaris as Chief Financial Officer and will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.
  • Loss for the fourth quarter of 2023 was €32.7 million, resulting in basic and diluted loss per share of €0.74.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
Montag, April 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
Montag, April 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Mittwoch, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Mittwoch, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

U.S. adults are still behind on routine cancer screenings—but reasons why vary by race

Retrieved on: 
Dienstag, April 2, 2024
Lung cancer, Health, Millennials, Child care, Confusion, Prostate cancer, Survival, Skin cancer, Disease, Colorectal cancer, Nervous, Risk, Cervical cancer, Heredity, Education, Patient, Cancer, Testicular cancer, Oral cancer, Generation Z, Breast cancer, Gen, Fear

The survey revealed that nearly seven in 10 U.S. adults are behind on at least one routine cancer screening.1

Key Points: 
  • The survey revealed that nearly seven in 10 U.S. adults are behind on at least one routine cancer screening.1
    The second annual survey, released during Cancer Prevention and Early Detection Month in April, indicates more U.S. adults are behind on routine cancer screenings compared to last year.
  • It is crucial to advocate for your health and talk to your health care provider about the routine cancer screenings you need.
  • “We are reaffirming our commitment to empowering people to stay ahead of cancer through prevention and early detection until all populations can achieve better outcomes—without any barriers to the process.”
    1The cancer screenings studied in this survey were for breast cancer, cervical cancer, colorectal cancer, lung cancer, oral cancer, prostate cancer, skin cancer and testicular cancer.
  • 2In this survey, Gen Z is defined as adults ages 21-27 and Millennials are defined as adults ages 28-43.

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Retrieved on: 
Dienstag, April 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neuroscience, Juno Therapeutics, Genentech, Cornell University, Heredity, Patient, Carmustine, Acquisition, Allergy, Senior, Research and development, Therapy, Drug development, Rituximab, Management

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.
  • Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
  • “It is a pleasure to welcome Sunil to our Board of Directors,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
  • “STAR-0215 has the potential to significantly improve the lives of patients and I look forward to contributing to its progress at this exciting time.”
    Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics.

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Retrieved on: 
Montag, März 18, 2024
Angioedema, Conference, EOP, Attack, Quality of life (healthcare), Network, Safety, HAE, Hereditary angioedema, Patient, Adolescence, Heredity, Country, National Congress, Physician, Medicine, Pharmaceutical industry

“We are committed to the continued advancement of our clinical development program of deucrictibant to fulfill unmet needs of current HAE treatment,” said Berndt Modig, Chief Executive Officer of Pharvaris.

Key Points: 
  • “We are committed to the continued advancement of our clinical development program of deucrictibant to fulfill unmet needs of current HAE treatment,” said Berndt Modig, Chief Executive Officer of Pharvaris.
  • The RAPIDe-3 study is designed to assess the effectiveness of deucrictibant in addressing that unmet need.
  • RAPIDe-3 is a randomized, double-blind, placebo-controlled, crossover study, which is designed to enroll approximately 120 adolescent and adult participants globally.
  • The data illustrates that HRQoL is negatively impacted, including functional and psychological impairment, in people with HAE.